中信股份(00267.HK)已認購併獲配合計5831萬股中信證券H股供股股份
格隆匯3月4日丨中信股份(00267.HK)公吿,就認購中信證券供股事項,公司已認購併獲配合計58,311,604股H股供股股份(包括公司暫定獲配的56,400,000股H股供股股份及1,911,604股H股額外申請項下的額外H股供股股份);及中信有限已認購併獲配299,954,362股A股供股股份。
緊隨本次供股完成後並截至本公吿日期,公司間接持有中信證券2,299,650,108股A股,並直接持有中信證券434,311,604股H股,合共佔中信證券經擴大已發行總股本的約18.45%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.